Robert M. Califf is commissioner of food and drugs at the US Food and Drug Administration. Califf is a nationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, and a leader in the growing field of translational research. He was also commissioner in 2016 and previously deputy commissioner for medical products and tobacco. Prior to rejoining the FDA in 2022, Califf was head of medical strategy and senior advisor at Alphabet, contributing to strategy and policy for its health subsidiaries Verily Life Sciences and Google Health. Prior to Alphabet, he was professor of medicine and vice chancellor for clinical and translational research at Duke University, director of the Duke Translational Medicine Institute, and founding director of the Duke Clinical Research Institute.
Previously
When he was sworn in as 25th commissioner of the US Food and Drug Administration in February 2022, Robert Califf knew the assignment would be intense because he had held the p...
More than $2.7 trillion worth of food, medical products, and tobacco, representing 20 percent of every dollar spent by US consumers, is regulated by the Food and Drug Administ...
The 3rd annual Spotlight Health is a deep-dive into issues around health, and it’s a momentous time for health. It’s becoming easier to alter human genes, and the Zika ep...
The Zika virus, first identified among humans in 1952 in Uganda, began spreading across the Americas and the Caribbean in 2015. Locally-acquired cases on the continental US ar...